Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Oct. 31, 2022	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Cash flows from operating activities:
Net (loss) income		$ (278,486)	$ 577,229	$ (1,150,292)	$ 4,944,891
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Bad debt expense - related party			(21,799)	105,465		$ 71,796
Loss on settlement of debt and accrued expense		1,500		1,850	151,559
Depreciation		5,442	5,898	16,328	17,088
Stock-based compensation					20,500
Stock-based loan modification cost			10,500		10,500
Amortization of convertible notes receivable discount				(2,731)	(16,215)
Change in fair value of convertible notes and derivatives		26,665	(1,019,736)	116,850	(6,569,581)
Amortization of loan discount				120,755	404,549
Amortization of operating lease right-of-use assets				57,509	50,414
Changes in operating assets and liabilities:
Decrease (increase) in accounts receivable				(305)	24,418
Increase in inventory				(5,221)	(9,557)
Increase in other receivable				(43,363)	(12,000)
Decrease (increase) in prepaid expenses and other current assets				(12,348)	(52,000)
Increase (decrease) in accounts payable				25,111	40,385
Increase in accrued expenses				146,285	112,056
Increase in accrued payroll due to officers				120,000	120,000
Increase in deferred revenue - related party				178,634	111,011
Increase (decrease) in accrued interest to related parties				17,231	1,252
Decrease in operating lease obligations				(55,565)	(57,670)
Net cash used in operating activities				(363,807)	(708,400)
Cash flows from investing activities:
Sale of Stemsation stock				33,516
Convertible notes receivable advances				(12,310)	(16,451)
Convertible notes receivable repayments				12,500	50,250
Acquisition of equipment					(57,993)
Net cash provided by (used) in investing activities:				33,706	(24,194)
Cash flows from financing activities:
Loans from officer				491,530	62,201
Repayment of officer loans				(132,800)	(204,000)
Proceeds from convertible notes				36,500	710,000
Repayment of convertible notes	$ (10,000)			(32,579)	(60,994)
Advances from other notes payable				182,200	251,340
Repayments of other notes payable				(214,750)	(116,863)
Net cash provided by financing activities				330,101	641,684
Net change in cash					(90,910)
Cash - beginning of period					90,910	90,910
Cash - end of period
Supplemental Cash Flow Information:
Cash paid for interest				75,555	84,460
Cash paid for income taxes
Non Cash Financing and Investing:
Common stock issued in settlement of notes					276,752
Common stock issued for conversion of debt				2,500	36,000
Warrants issued with Debt —Debt discount					100,000
Stemsation shares awarded but not yet issued in settlement of convertible notes receivable				195,284
Stemsation shares received in settlement of convertible notes receivable				68,716
Reclassification of other receivable to convertible notes receivable				$ 39,363	$ 15,000

NUTRA PHARMA CORP 10-Q